Fundraising Fox

Chris Sullivan

Investor

Chief Financial Officer at Avalo Therapeutics

About

CFO since February 2022 with strong public company and life sciences finance background. Previously served as Corporate Controller at Sucampo Pharmaceuticals (during its $1.2 billion merger with Mallinckrodt) and OpGen. Experienced in capital raises, M&A transactions, and enterprise resource planning in biotech and pharmaceutical sectors.

Colleagues at Avalo Therapeutics